• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Novo Nordisk A/S ADR (NY: NVO )

    134.89 -2.17 (-1.58%)
    Official Closing Price Updated: 7:00 PM EDT, Aug 16, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,111,271
    Open 135.40
    Bid (Size) 134.99 (1)
    Ask (Size) 135.39 (3)
    Prev. Close 137.06
    Today's Range 134.66 - 135.67
    52wk Range 86.96 - 148.15
    Shares Outstanding N/A
    Dividend Yield 1.31%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived
    Eli Lilly has a lot going for it. 
    Via The Motley Fool
    Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
    Should Novo Nordisk and Eli Lilly investors be worried about Roche? 
    Via The Motley Fool

    Performance

    YTD
    +32.10%
    +32.10%
    1 Month
    +3.77%
    +3.77%
    3 Month
    +1.49%
    +1.49%
    6 Month
    +11.07%
    +11.07%
    1 Year
    +47.32%
    +47.32%

    More News

    Read More
    These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
    Via The Motley Fool
    Is Madrigal Pharmaceuticals Stock a Buy?
    Via The Motley Fool
    3 Fantastic Growth Stocks to Buy in August
    Via The Motley Fool
    Could Viking Therapeutics Become the Next Novo Nordisk?
    Via The Motley Fool
    Unpacking the Latest Options Trading Trends in Novo Nordisk
    Via Benzinga
    Doctors Struggle to Secure Medicare Coverage for Heart Patients on Novo Nordisk's Wegovy
    Via Benzinga
    Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market
    Via Benzinga
    Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater
    Via The Motley Fool
    Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)
    Via The Motley Fool
    Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
    Via Investor's Business Daily
    Is Novo Nordisk's Earnings Miss a Cause for Concern for Investors?
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Don't Promote Copycat Weight-Loss Drugs Amid Improved Supply, Eli Lilly Asks Doctors, FDA Evaluates
    Via Benzinga
    Exposures Product Safety
    Eli Lilly Smashed Estimates Thanks To Unbelievable Demand For Its Diabetes And Weight Loss Blockbusters
    Via Benzinga
    3 Stable Blue-Chip Stocks to Buy for the Market Storm
    Via InvestorPlace
    This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock
    Via The Motley Fool
    Being Vain Has Its Benefits. Why Eli Lilly And The 'Me-Conomy' Are Here To Stay.
    Via Investor's Business Daily
    3 Biotech Stocks Poised for a Comeback After Last Week’s Market Meltdown
    Via InvestorPlace
    Novo Nordisk Just Hit 3 Snags in a Row. Is Its Stock Still a Buy?
    Via The Motley Fool
    This 1 Piece of Good News for Eli Lilly Is Bad News for Hims & Hers Health Stock
    Via The Motley Fool
    Weight Loss Drugs Like Ozempic, Zepbound May Reduce Cancer Risks, Studies Suggest
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Weight Loss Stocks Could Become Alzheimer's Drugs Stocks. Here's Why That's Bullish for Novo Nordisk
    Via The Motley Fool
    MarketBeat Week in Review – 8/5 - 8/9
    Via MarketBeat
    Topics Economy
    Exposures Economy Interest Rates
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.